Porphyria Cutanea Tarda
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Porphyria cutanea tarda (PCT) is the most common human porphyria, due to hepatic deficiency of uroporphyrinogen decarboxylase (UROD), which is acquired in the presence of iron overload and various susceptibility factors, such as alcohol abuse, smoking, hepatitis C virus (HCV) infection, HIV infection, iron overload with HFE gene mutations, use of estrogens, and UROD mutation.
|
30683557 |
2019 |
Porphyria Cutanea Tarda
|
0.600 |
Biomarker
|
disease |
BEFREE |
Few studies have examined the connection between PCT and the regulation of iron metabolism genes other than the HFE gene.
|
29774528 |
2018 |
Porphyria Cutanea Tarda
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Investigation of porphyria cutanea tarda association with C282Y and H63D mutations in the HFE gene.
|
24068123 |
2014 |
Porphyria Cutanea Tarda
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Mutations of the UROD and hemochromatosis (HFE) genes are genetic factors in some PCT patients which can be mimicked in mice heterozygous for the Hfe and Urod null genes.
|
20099833 |
2010 |
Porphyria Cutanea Tarda
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Hemochromatosis gene (HFE) mutations and the hepatitis C virus (HCV) are known risk factors for porphyria cutanea tarda (PCT), but interactions with erythrocytic uroporphyrinogen decarboxylase (UROD) have seldom been addressed.
|
19001803 |
2009 |
Porphyria Cutanea Tarda
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The HFE gene mutations were detected in 70% of patients with PCT compared with 35% in the control group (P < 0.001).
|
18565178 |
2008 |
Porphyria Cutanea Tarda
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Porphyria cutanea tarda associated with Cys282Tyr mutation in HFE gene in hereditary hemochromatosis: a case report and review of the literature.
|
18189029 |
2007 |
Porphyria Cutanea Tarda
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The pertinence of HFE mutations, anastrozole and tamoxifen treatment, and chemotherapy to the development and management of PCT in women with breast cancer is discussed.
|
17919354 |
2007 |
Porphyria Cutanea Tarda
|
0.600 |
Biomarker
|
disease |
LHGDN |
HFE gene in primary and secondary hepatic iron overload.
|
17729389 |
2007 |
Porphyria Cutanea Tarda
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The prevalence of HFE C282Y gene mutation is increased in Spanish patients with porphyria cutanea tarda without hepatitis C virus infection.
|
17062032 |
2006 |
Porphyria Cutanea Tarda
|
0.600 |
GeneticVariation
|
disease |
LHGDN |
The prevalence of HFE C282Y gene mutation is increased in Spanish patients with porphyria cutanea tarda without hepatitis C virus infection.
|
17062032 |
2006 |
Porphyria Cutanea Tarda
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Our results comprise the first molecular studies of both common and rare hemochromatosis gene variants in German PCT patients, indicating a significant role of the C282Y mutation in the pathogenesis of PCT.
|
17298224 |
2006 |
Porphyria Cutanea Tarda
|
0.600 |
GeneticVariation
|
disease |
LHGDN |
Our results comprise the first molecular studies of both common and rare hemochromatosis gene variants in German PCT patients, indicating a significant role of the C282Y mutation in the pathogenesis of PCT.
|
17298224 |
2006 |
Porphyria Cutanea Tarda
|
0.600 |
Biomarker
|
disease |
LHGDN |
Association of porphyria cutanea tarda with hereditary hemochromatosis.
|
15280838 |
2004 |
Porphyria Cutanea Tarda
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Hemochromatosis (HFE) gene mutations and hepatitis C virus infection as risk factors for porphyria cutanea tarda in Hungarian patients.
|
15101996 |
2004 |
Porphyria Cutanea Tarda
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The recent increasing contribution of hepatitis C virus infection to PCT in Japan has also been recognized. but there have been no PCT cases in Japan with HFE gene mutations.
|
15239394 |
2004 |
Porphyria Cutanea Tarda
|
0.600 |
GeneticVariation
|
disease |
LHGDN |
The prevalence of C282Y and H63D mutations in the HFE gene was determined in 50 PCT patients and compared with the reported control frequencies.
|
15101996 |
2004 |
Porphyria Cutanea Tarda
|
0.600 |
Biomarker
|
disease |
BEFREE |
HFE gene analysis should be done in patients who present with porphyria cutanea tarda.
|
15280838 |
2004 |
Porphyria Cutanea Tarda
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Hemochromatosis (HFE) gene mutations and response to chloroquine in porphyria cutanea tarda.
|
12622622 |
2003 |
Porphyria Cutanea Tarda
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Results of recent studies have demonstrated high prevalences (about 60%-80%) of HFE gene mutations in patients with porphyria cutanea tarda.
|
12957298 |
2003 |
Porphyria Cutanea Tarda
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
To investigate the relations between hemochromatosis gene (HFE) mutations and PCT in the south of France and their links with chronic hepatitis C virus (HCV) infection.
|
12673077 |
2003 |
Porphyria Cutanea Tarda
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Recent reports have described a significant association between inheritance of the C282Y and H63D mutations in the HFE gene, associated with genetic hemochromatosis (GH) and PCT.
|
12699243 |
2002 |
Porphyria Cutanea Tarda
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
To evaluate the incidence and spectrum of HFE mutations and the relative frequency of the two main alleles of transferrin receptor in patients with PCT originating from southern France, and to evaluate the relationship of these genetic data with iron status, and with hepatitis B and C and human immunodeficiency virus (HIV) infections.
|
11260010 |
2001 |
Porphyria Cutanea Tarda
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Inherited factors that may predispose to PCT include the C282Y mutation in the hemochromatosis (HFE) gene.
|
11499833 |
2001 |
Porphyria Cutanea Tarda
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
This study, comprising 108 patients with PCT, was intended to define the role of hemochromatosis gene (HFE) mutations in the expression of PCT and to determine the contribution of acquired factors including alcohol, hepatitis C virus (HCV), and estrogen.
|
10688809 |
2000 |